DRUGDOCS | Omegaven®

Drug updated on 12/11/2024

Dosage Form	Injection (intravenous; 5 g/50 mL, 10 g/100 mL)
Drug Class	Fatty acids
Ongoing and Completed Studies	ClinicalTrials.gov

Indication

Indicated as a source of calories and fatty acids in pediatric patients with parenteral nutrition-associated cholestasis (PNAC).

This summary is based on the review of one systematic review/meta-analysis. ^[1]
Reduction in Parenteral Nutrition-Associated Cholestasis (PNAC) Incidence: Fish oil-containing lipid emulsions significantly reduced the occurrence of PNAC in very low birth weight (VLBW) infants, with a risk ratio (RR) of 0.53 (95% CI: 0.36-0.80, P = 0.002).
Effectiveness in Subgroups: The efficacy of fish oil emulsions was particularly notable in infants receiving parenteral nutrition for more than 14 days (RR = 0.47, 95% CI: 0.30-0.73, P = 0.0008) and in those with a birth weight below 1000 grams (RR = 0.53, 95% CI: 0.33-0.85, P = 0.009).
There is no safety information available in the reviewed studies.
Fish oil-containing lipid emulsions significantly reduced the occurrence of PNAC in VLBW infants, especially those with a birth weight below 1000 grams and in infants receiving parenteral nutrition for more than 14 days.

Document Title	Year	Source
Omegaven (fish oil triglycerides) Prescribing Information.	2023	Fresenius Kabi USA, LLC., Lake Zurich, IL

Document Title	Year	Source
Fish oil-containing lipid emulsions prevention on parenteral nutrition-associated cholestasis in very low birth weight infants: a meta-analysis	2022	World Journal of Pediatrics

Document Title	Year	Source
Standardised neonatal parenteral nutrition formulations - Australasian neonatal parenteral nutrition consensus update 2017	2020	BMC Pediatrics
ESPEN practical guideline: Clinical nutrition in liver disease	2020	Clinical Nutrition